Immedica’s partner Actinium announces Iomab-B phase 3 SIERRA trial results in patients with a TP53 mutation presented in an oral presentation at the 50th EBMT annual meeting
Stockholm, April 18, 2024 – Immedica’s partner Actinium Pharmaceuticals, Inc. presented results from the Phase 3 SIERRA trial of Iomab-B in patients with a TP53 mutation in an oral presentation at the 50th Annual meeting of the European Society for Blood and Marrow Trasnplantation (EBMT) held April 14 – 17, 2024, in Glasgow, Scotland. Iomab-B is a targeted radiotherapy agent comprised of an anti-CD45 monoclonal antibody conjugated to Iodine-131 radioisotope payload. The Phase 3 SIERRA trial enrolled 153 patients with active relapsed or refractory acute myeloid leukemia (r/r AML) and